Gadoterate meglumine decreases ADC values of breast lesions depending on the b value combination

Sci Rep. 2018 Jan 8;8(1):87. doi: 10.1038/s41598-017-18035-0.

Abstract

To retrospectively evaluated the influence of administration of the gadolinium based intravenous contrast agent (G-CA) on apparent diffusion coefficient (ADC) values in ADC maps generated using multiple b value combinations. A total of 106 women underwent bilateral 3.0 T breast MRI. As an internal validation, diffusion-weighted imaging (b values of 0, 200, 400, 600, 800 s/mm2) was performed before and after the G-CA (gadoterate meglumine (0.2 ml/kg, 3 ml/s)). Whole lesion and fibroglandular tissue (FGT) covering region-of-interests (ROIs) were drawn on the b = 800 s/mm2 images; ROIs were then propagated to multiple retrospectively generated ADC maps. Twenty-seven patients (mean age 55.8 ± 10.8 years) with 32 mass-like enhancing breast lesions including 25 (78.1 %) histopathologically malignant lesions were enrolled. Lesion ADC values were statistically significantly higher in pre-G-CA than post-G-CA ADC maps (ADC0,200,400,600,800: 1.05 ± 0.35 × 10-3 mm2/s vs. 1.02 ± 0.36 × 10-3 mm2/s (P < 0.05); ADC0,200,400: 1.25 ± 0.42 × 10-3 mm2/s vs. 1.20 ± 0.35 × 10-3 mm2/s (P < 0.05)). ADC values between pre- and post-contrast maps were not statistically different when the maps were generated using other b value combinations. Contrast agent administration did not affect the FGT ADC values. G-CA statistically significantly reduced the ADC values of breast lesions on ADC maps generated using the clinically widely utilized b values.

MeSH terms

  • Aged
  • Biopsy
  • Breast / diagnostic imaging*
  • Breast / pathology*
  • Breast Neoplasms / diagnostic imaging
  • Breast Neoplasms / pathology
  • Contrast Media / administration & dosage*
  • Contrast Media / pharmacokinetics*
  • Diffusion Magnetic Resonance Imaging* / methods
  • Female
  • Humans
  • Image Enhancement
  • Meglumine / administration & dosage*
  • Meglumine / pharmacokinetics*
  • Middle Aged
  • Organometallic Compounds / administration & dosage*
  • Organometallic Compounds / pharmacokinetics*
  • Tissue Distribution
  • Tumor Burden

Substances

  • Contrast Media
  • Organometallic Compounds
  • Meglumine
  • gadoterate meglumine